Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

Overview of attention for article published in JAMA Oncology, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

news: 1 news outlet
twitter: 48 X users
patent: 2 patents
facebook: 1 Facebook page

googleplus: 2 Google+ users
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 136 Mendeley

So far, Altmetric has seen 6 public wall posts from 1 users.

JAMA Oncology, 10 Jan 2018

This validated model derived from 1100 patients with AML demonstrates that patient comorbidities are significantly associated…

JAMA Oncology, 10 Jan 2018

This cohort study examines the prognostic association of comorbidities on 1-year mortality after initial therapy of acute…

JAMA Oncology, 09 Oct 2017

Open Access from the JAMA Network: Acute Myeloid Leukemia–Composite Model for Mortality Risk Estimates http://ja.ma/2fV2XEh

JAMA Oncology, 09 Sep 2017

This cohort study examines the prognostic association of comorbidities on 1-year mortality after initial therapy of acute…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 2 additional Facebook posts.